IBCSG 55-17 TOUCH

  • Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer.

  • Trial Co-Chair
    Laura Biganzoli, MD, Prato, Italy
    Etienne Brain, MD, PhD, Paris, France 

    Trial Coordinator
    Meredith Kissel 

    Director of the Data Management Center
    Holly Shaw

    Statistician 
    Svitlana Tyekucheva 


    IBCSG Data Management Center/Frontier Science Foundation
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

     

    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    Feb 28, 2018 

    Final Accrual
    147 

    Date last patient was randomized
    July 28, 2022

    Protocol Release Date
    Feb 28, 2018 

    Trial Activation Date
    Oct 04, 2018

    First Patient In
    April 16, 2019

    Accrual Closure Date
    August 03, 2022 

    Global Trial Completion Date 
    April 20, 2023

     

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login